title: Rhabdomyolysis during therapy with daptomycin.
abstract: The use of daptomycin has been associated with an elevation in creatine phosphokinase level, with a reported incidence of 2.8% in phase III clinical trials. Published case reports have documented the presence of myopathy in patients who received daptomycin; however, there have been no previously reported cases of rhabdomyolysis in animals or humans to date. We describe a case of rhabdomyolysis during therapy with daptomycin.
authors.affiliation: Department of Pharmacy, University of Kentucky Chandler Medical Center, Lexington, Kentucky 40536, USA. spapa2@email.uky.edu
authors.forename: Stella
authors.initials: S
authors.lastname: Papadopoulos
authors.forename: Amanda M
authors.initials: AM
authors.lastname: Ball
authors.forename: Susanne E
authors.initials: SE
authors.lastname: Liewer
authors.forename: Craig A
authors.initials: CA
authors.lastname: Martin
authors.forename: P Shane
authors.initials: PS
authors.lastname: Winstead
authors.forename: Brian S
authors.initials: BS
authors.lastname: Murphy
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017576:Daptomycin / Q000009:adverse effects* / Q000627:therapeutic use; D016984:Enterococcus faecium; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D008875:Middle Aged; D012206:Rhabdomyolysis / Q000139:chemically induced*
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin